Metabolon, headquartered in Morrisville, NC, has successfully obtained a $60 million credit facility from Trinity Capital. The financing will serve as a catalyst for the company’s growth initiatives, enabling it to expand its research and development efforts to enhance its metabolomics platform further. Additionally, the funds will support Metabolon’s global expansion plans, including market penetration initiatives and strategic partnerships.
Under the leadership of CEO Rohan (Ro) Hastie, Metabolon has positioned itself as the global leader in metabolomics, specializing in providing metabolomics solutions for various life science applications, including research, diagnostics, therapeutic development, and precision medicine. With over 20 years of experience, the company has conducted over 10,000 projects, resulting in 3,000+ publications. Metabolon’s ISO 9001:2015, CLIA, and CAP certifications underscore its commitment to delivering high-quality biochemical data and insights to its customers.
Metabolon’s metabolomics platform, complemented by its proprietary metabolomics reference library and expertise in data analysis and translational science, enables customers to address complex questions in life sciences research effectively. The company offers scalable and customizable multiomics solutions, including metabolomics and lipidomics, to support customers throughout the research and development lifecycle.
Rohan (Ro) Hastie expressed enthusiasm about the investment, emphasizing Metabolon’s role in advancing precision medicine through its innovative metabolomics solutions. He highlighted the company’s commitment to driving growth, innovation, and leadership in the metabolomics space.
With the infusion of capital from Trinity Capital, Metabolon is well-positioned to accelerate its trajectory as a key player in the life sciences industry, driving advancements in metabolomics and contributing to the realization of precision medicine goals.
